



## Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference

August 2, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2018-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that company management will present a corporate overview at the Canaccord Genuity 38<sup>th</sup> Annual Growth Conference on Thursday, Aug. 9, 2018 at 1:30 p.m. ET in Boston.

A live webcast of the company's presentation will be accessible from the Investors & Media section of Sesen Bio's website, [www.sesenbio.com](http://www.sesenbio.com). An archived replay of the webcast will be available on the company's website for 90 days after the conference.

### About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company's Targeted Protein Therapeutics platform. The company's lead program, Vicinium™, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment of high-grade non-muscle invasive bladder cancer. Vicinium incorporates a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively and effectively kill cancer cells while sparing healthy cells. For more information, please visit the company's website at [www.sesenbio.com](http://www.sesenbio.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180802005160/en/>

Source: Sesen Bio, Inc.

THRUST Strategic Communications

Monique Allaire, 617-895-9511

[monique@thrustir.com](mailto:monique@thrustir.com)

or

Alicia Davis, 910-620-3302

[alicia@thrustir.com](mailto:alicia@thrustir.com)